SAN Sanofi

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

PARIS, France – March 4, 2021 - Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

These documents are available on the company’s website: .

In addition, the Form 20-F is available on the website of the SEC () and the “Document d’Enregistrement Universel” is available on the website of the AMF (). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

 



About Sanofi



 



Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.



 



With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.



 



Sanofi, Empowering Life



 





Media Relations Contact

Ashleigh Koss

Tel: +1 (908) 981-8745





 



Sandrine Guendoul

Tel.: +33 (0)1 53 77 46 46









 
 



Investor Relations Contacts Paris

Eva Schaefer-Jansen

Arnaud Delepine

Yvonne Naughton



 



Investor Relations Contacts North America

Felix Lauscher

Fara Berkowitz

Suzanne Greco



 



IR main line:

Tel.: +33 (0)1 53 77 45 45





 







 



Attachment



EN
04/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Sanofi’s Sarclisa approved in the EU for the treatment ...

Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd aloneWith the first global approval in TE NDMM, Sarclisa is now approved in the EU across all lines of therapy, regardless of transplant eligibility Paris, July 25, 2025. Foll...

 PRESS RELEASE

Communiqué de presse : Sarclisa de Sanofi approuvé dans l’UE pour le t...

Communiqué de presse : Sarclisa de Sanofi approuvé dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe Sarclisa de Sanofi approuvé dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe Approbation fondée sur l’étude de phase 3 GMMG-HD7, qui a montré que l’ajout de Sarclisa au traitement d’induction VRd améliorait significativement le taux de négativité de la MRD (maladie résiduelle minimale) et prolongeait la SSP (survie sans progression) par rapport au VRd seulA...

 PRESS RELEASE

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccin...

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK. The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ tec...

 PRESS RELEASE

Communiqué de presse : Sanofi va acquérir Vicebio et enrichir son pipe...

Communiqué de presse : Sanofi va acquérir Vicebio et enrichir son pipeline de vaccins respiratoires Sanofi va acquérir Vicebio et enrichir son pipeline de vaccins respiratoires Paris, le 22 juillet 2025. Sanofi annonce aujourd'hui la conclusion d'un accord pour l'acquisition de Vicebio Ltd (« Vicebio »), une société de biotechnologie privée dont le siège est à Londres, au Royaume-Uni. Cette acquisition apporte à Sanofi un candidat-vaccin combiné en phase précoce de développement contre le virus respiratoire syncytial (VRS) et le métapneumovirus humain (hMPV), deux virus respiratoires, et r...

 PRESS RELEASE

Press Release: Sanofi completes acquisition of Blueprint Medicines

Press Release: Sanofi completes acquisition of Blueprint Medicines Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases. In addition, the acquisition of Blueprint brings Sanofi an established presence among allergists, dermatologists, and immunologists which is expected to enhance Sanofi’s ability to a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch